BLCAM Double Nickase Plasmid (h): sc-401451-NIC
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- CD22 Double Nickase Plasmid (h) consists of a pair of plasmids each encoding a D10A mutated Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed to knockout gene expression with greater specificity than its CRISPR/Cas9 KO counterpart
- Paired gRNA sequences are offset by approximately 20 bp to allow for specific Cas9-mediated double nicking of the genomic DNA, which mimics a DSB
- One plasmid in the pair contains a puromycin-resistance gene for selection; the other plasmid in the pair contains a GFP marker to visually confirm transfection
- CD22 Double Nickase Plasmid (h) and CD22 Double Nickase Plasmid (h2) encode distinct paired gRNA designs targeting CD22. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: CD22 Antibody (D-5): sc-271579
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
BLCAM Double Nickase Plasmid (h) | sc-401451-NIC | 20 µg | $410.00 | |||
CD22 Double Nickase Plasmid (h2) | sc-401451-NIC-2 | 20 µg | $410.00 |
Human CD22, also known as BLCAM, is a B cell–restricted sialic acid–binding immunoglobulin-like lectin that functions as an inhibitory co-receptor of the B cell antigen receptor (BCR). Upon BCR engagement, CD22 becomes phosphorylated and recruits SHP-1 phosphatase, dampening downstream kinase signaling and tuning calcium flux, MAPK activation, and PI3K-linked pathways that shape B cell activation and tolerance. Through its role in controlling signaling thresholds and promoting immune homeostasis, CD22 contributes to regulation of antigen responsiveness, survival cues, and maintenance of peripheral B cell self-tolerance. Dysregulated CD22 signaling or expression has been associated with aberrant B cell activation states relevant to autoimmunity and B cell–derived malignancy biology, supporting its use in mechanistic studies of BCR pathway control.
CD22 Double Nickase Plasmid (h) consists of a matched pair of plasmids engineered for high-specificity editing of the CD22 locus in human cell lines. Each plasmid expresses a Cas9 D10A nickase and a distinct sgRNA targeting opposite DNA strands within CD22. When directed to adjacent sites on opposite DNA strands, the two nickases generate offset single-strand nicks that together produce a staggered double-strand break, requiring coordinated on-target activity from both guides. The resulting DNA break is resolved by endogenous cellular repair pathways, most commonly through non-homologous end joining (NHEJ), leading to insertions or deletions that disrupt CD22 function. By requiring dual sgRNA engagement at the target locus, the double nicking approach enhances editing specificity and provides a complementary CRISPR strategy for applications where additional control over targeting precision is desired.
To support efficient identification of edited cells, one plasmid encodes GFP for fluorescent visualization of transfected populations, while the companion plasmid carries a puromycin resistance gene for antibiotic selection. Together, these features support efficient enrichment of co-transfected populations and simplify the validation of CD22-disrupted clones.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.